A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and any good and bad side effects of
combining 2 study drugs, copanlisib and ibrutinib. This combination of drugs could shrink
your Mantle Cell Lymphoma (MCL), but it could also cause side effects. Both these drugs have
been given to people before, but this is the first time that they are being given together.